Cargando…

129. Beta-lactam vs Fluoroquinolone Monotherapy for pseudomonas Aeruginosa infection: A Systematic Review and Meta-analysis

BACKGROUND: Pseudomonas aeruginosa (PA) is a leading cause of healthcare-associated infections, including pneumonia, bloodstream infections, and surgical site infections around the world. A variety of antibiotic classes are used in the treatment of PA infections, including beta-lactams (BLs) and flu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reid, Eric C, Walters, Ryan, Destache, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777921/ http://dx.doi.org/10.1093/ofid/ofaa439.439

Ejemplares similares

Beta-Lactam vs. Fluoroquinolone Monotherapy for Pseudomonas aeruginosa Infection: A Systematic Review and Meta-Analysis
por: Reid, Eric, et al.
Publicado: (2021)

271. Clinical Outcomes Treating Gram-Negative Bacteremia with Oral Beta-Lactams vs. Trimethoprim-Sulfamethoxazole or Fluoroquinolone Step-Down Therapy
por: Sinclair, Emily, et al.
Publicado: (2020)

277. Comparison of Oral Beta-Lactams and Fluoroquinolones for Step-Down in Uncomplicated Enterobacterales Blood Stream Infections
por: Ngo, Nichol, et al.
Publicado: (2020)

1114. Effectiveness and Safety of Beta-lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2021)

308. Re-purposing Beta-lactam Antibiotics as Fluoroquinolone Sparing Stepdown Therapy for the Treatment of Enterobacteriales Bloodstream Infections
por: Davis, Matthew, et al.
Publicado: (2020)

1297. Azithromycin vs Beta Lactams in Acute Exacerbations of COPD
por: Kale-Pradhan, Pramodini, et al.
Publicado: (2021)

Impact of Definitive Therapy with Beta-Lactam Monotherapy or Combination with an Aminoglycoside or a Quinolone for Pseudomonas aeruginosa Bacteremia
por: Bliziotis, Ioannis A., et al.
Publicado: (2011)

254. Review of Clinical Outcomes in Patients Treated with Beta-lactam vs Non-beta-lactam Therapy for AmpC Producing Bacterial Bloodstream Infections
por: Staicu, Mary L, et al.
Publicado: (2020)

1072. Streamlining to Oral β-Lactam vs. Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
por: Fong, Karen, et al.
Publicado: (2018)

Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis
por: Liu, Sitong, et al.
Publicado: (2019)

165. Comparative Effectiveness of Oral Fluoroquinolones vs. β-Lactams for the Treatment of Patients with Enterobacteriaceae Bloodstream Infections
por: Bjork, Lauren, et al.
Publicado: (2019)

834. Clinical Outcomes with Carbapenem-Resistant Pseudomonas aeruginosa that Retain Susceptibility to Traditional Antipseudomonal β-lactams: Atlanta, 2016-2018
por: Howard-Anderson, Jessica, et al.
Publicado: (2020)

1450. Frequency of Carbapenem-resistant Pseudomonas aeruginosa Among Respiratory Pathogens Impacts First-Line Beta-Lactam Susceptibility: Potential Role for Ceftolozane/Tazobactam (C/T) and/or Imipenem/Relebactam (I/R)
por: Klinker, Kenneth, et al.
Publicado: (2020)

1600. Susceptibility of β-Lactam-Resistant Pseudomonas aeruginosa to Other β-Lactams: Is There Truly a Lack of Cross-Resistance?
por: Patel, Twisha S, et al.
Publicado: (2019)

185. Pseudomonas aeruginosa (PA) Bacteremia and Patient Outcome during COVID-19 Pandemic
por: Vivekanandan, Renuga, et al.
Publicado: (2023)

129. Antimicrobial Stewardship Intervention Bundle Decreases Fluoroquinolone Prescribing for Urinary Tract Infection in Urgent Care and Primary Care Clinics
por: Cubillos, Ashley L, et al.
Publicado: (2020)

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?
por: Sansom, Sarah, et al.
Publicado: (2019)

1601. Evaluation of Synergy with β-Lactams Plus Aztreonam Against Pseudomonas aeruginosa (PSA)
por: O’Donnell, J Nicholas, et al.
Publicado: (2019)

2269. Clinical Outcomes in Patients with Carbapenem-Non-Susceptible, β-Lactam-Susceptible Pseudomonas aeruginosa Infections
por: Gavaghan, Victoria M, et al.
Publicado: (2019)

Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use
por: MacDougall, Conan, et al.
Publicado: (2005)

Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa
por: Zhao, Lei, et al.
Publicado: (2020)

1184. Activity of anti-pseudomonal antibiotics among all Pseudomonas aeruginosa (PSA) at an academic medical health system, including β-lactam, multi-drug (MDR) and extensively drug resistant (XDR) strains
por: Rose, Warren, et al.
Publicado: (2020)

Effectiveness of empiric aztreonam compared to other beta-lactams for treatment of Pseudomonas aeruginosa infections
por: Hogan, Michael, et al.
Publicado: (2018)

In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
por: Spottiswoode, Natasha, et al.
Publicado: (2023)

Beta lactam hypersensitivities
por: Azoury, Marie Eliane*, et al.
Publicado: (2014)

1822. Clinical Outcomes Associated with Oral Beta-Lactam Therapy versus Oral Fluoroquinolones/TMP-SMX for Uncomplicated Gram-Negative Bacteremia
por: Kaur, Satwinder S, et al.
Publicado: (2022)

181 Empiric Coverage of ICU Patients for Infections Due to Beta-lactam Resistant Pseudomonas aeruginosa with Combination Therapy: A Needs Assessment
por: Cawcutt, Kelly, et al.
Publicado: (2014)

162. Assessment of Beta-lactam Allergies as Rationale for Receipt of Vancomycin for Surgical Prophylaxis
por: Tucker, Kendall J, et al.
Publicado: (2020)

2798. Difficult to treat GES and KPC harboring Pseudomonas aeruginosa: Evaluation of in vivo efficacy of ß-lactam/ß-lactamase inhibitor humanized exposure vs. in vitro efficacy
por: Ruiz, Victor H, et al.
Publicado: (2023)

1628. Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia
por: Caffrey, Aisling, et al.
Publicado: (2020)

1805. Safety Outcomes Following Beta-Lactam use in Patients with a Documented Beta-Lactam Allergy
por: Rampersad, Daniel, et al.
Publicado: (2022)

722. Risk Factors for Infection or Colonization with Ceftolozane/Tazobactam Non-Susceptible Extensively β-Lactam Resistant Pseudomonas aeruginosa
por: Lee, Michelle, et al.
Publicado: (2023)

584. Ventricular assist device infections with Pseudomonas aeruginosa
por: Roberts, Scott C, et al.
Publicado: (2020)

85. The Impact of Carbapenem-Sparing Interventions on the Evolution of Resistance in Pseudomonas aeruginosa in the USA
por: Townsend, Jeffrey, et al.
Publicado: (2020)

728 Evaluation of Empirical Regimens Including Antistaphylococal Beta-lactam Antibiotics vs Vancomycin Monotherapy on Outcomes of Patients with Methicillin-Susceptible Staphylococcus aureus (MSSA) Bacteremia
por: Terico, Adrienne, et al.
Publicado: (2014)

1237. Characterization and crystallization of OXA-935, a novel class D OXA-10-like beta-lactamase, found in Pseudomonas aeruginosa
por: Pincus, Nathan B, et al.
Publicado: (2021)

1689. Oral Beta-lactam Step Down in Bacteremic E. coli Urinary Tract Infections
por: Saad, Stephan, et al.
Publicado: (2020)

884. Evaluation of Surgical Site Infections in Solid Organ Transplant Recipients with Beta-Lactam Allergies
por: Mowrer, Clayton, et al.
Publicado: (2020)

906. Surgical Site Infections in Children with Beta-Lactam Allergy: A Matched Cohort Study
por: Huang, Felicia Scaggs, et al.
Publicado: (2020)

Plasmid-Mediated Fluoroquinolone Resistance in Pseudomonas aeruginosa and Acinetobacter baumannii
por: Venkataramana, Geetha P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_85a3p54650qi6s9jgnq8fijah9